Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE trial registry — 297 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

HOFFMANN-LA ROCHE clinical trials

Registry index of 297 ClinicalTrials.gov studies linked to HOFFMANN-LA ROCHE programs — each row shows trial ID, program name, phase, status, and indication.

HOFFMANN-LA ROCHE trial registry — 297 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for HOFFMANN-LA ROCHE.

  1. MO43110 — Phase 3

    Clinical update

  2. GO29431 — Phase 3

    Clinical update

  3. WO29637 — Phase 3

    Clinical update

  4. MO29872 — Phase 3

    Clinical update

  5. YO29232 — Phase 3

    Clinical update

  6. ML43332 — Phase 2

    Clinical update

  7. GO43075 — Phase 2

    Clinical update

  8. CR44829 — Phase 3

    Clinical update

Trial registry

297 studies
  16. 2023-503629-20-00

    CO40115

    Phase 2 active small_molecule

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    CTIS ↗
  26. 2023-504084-17-00

    ALECTINIB

    Phase 2 active small_molecule

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    CTIS ↗
  30. 2023-504263-16-00

    BX44273

    Phase 3 active small_molecule

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    CTIS ↗
  34. 2023-504342-55-00

    RO5541267

    Phase 3 active small_molecule

    Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)

    CTIS ↗
  71. 2023-506310-43-00

    WP43295

    Phase 1 active other

    BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases

    CTIS ↗
  91. 2023-506861-76-00

    BO40336

    Phase 3 active small_molecule

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    CTIS ↗
  105. 2023-507497-40-00

    BO42203

    Phase 1 active other

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    CTIS ↗
  147. 2024-516162-11-00

    WO45654

    Phase 3 active small_molecule

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    CTIS ↗
  176. 2025-522805-39-00

    WO46063

    Phase 2 active small_molecule

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    CTIS ↗
  177. 2025-523013-28-00

    CO46274

    Phase 2 active small_molecule

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    CTIS ↗
  183. 2025-524498-17-00

    WO46069

    Phase 3 active small_molecule

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.